Targets › ZNT2
1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Aug 2027.
[Isoform 1]: Electroneutral proton-coupled antiporter concentrating zinc ions into a variety of intracellular organelles including endosomes, zymogen granules and mitochondria. Thereby, plays a crucial role in cellular zinc homeostasis to confer upon cells protection against its potential cytotoxicity. (UniProt, Q9BRI3)
Open in Phaseline: the race on ZNT2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Anhui Provincial Hospital | Oral elemental zinc supplementation Zinc supplementation (cofactor for immune cell function) | ZNT1, ZNT2 | Phase 2 | Hepatocellular Carcinoma | Aug 2027 |
Hepatocellular Carcinoma (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.